SymBio Pharmaceuticals Limited

4582.T
Drug Manufacturers - Specialty & Generic
2026/11/06 19:48 Updated
Market Cap: $34.4M (¥5.5B)
Stock Price: $0.43 (¥68)
Exchange Rate: 1 USD = ¥158.23

Notice Regarding Massive Exercising of the 70th Stock Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause)

Massive exercising of stock acquisition rights occurred up to November 6. Number of shares to be delivered: 5,600,000 shares; number of stock acquisition rights exercised: 56,000; proportion of total issued: 11.7%. Unexercised rights decreased from 328,460 to 272,460. This qualifies as exercising exceeding 10%.

Importance:
Page Updated: November 9, 2026
IR Disclosure Date: November 9, 2026

Key Figures

  • Number of shares to be delivered: 5,600,000 shares
  • Number of unexercised stock acquisition rights: 272,460
  • Total issued stock acquisition rights: 480,000 → 11.7% exercised

AI要約

Status and Scale of Massive Exercising

This announcement reports on the massive exercising of the 70th stock acquisition rights. The number of shares to be delivered is 5,600,000 shares. The exercise price is undisclosed. The number of stock acquisition rights exercised is 56,000, representing 11.7% of the total issued. The number of issued shares at the end of the previous month for the target month was 87,378,960 shares, of which treasury shares are 91,394. Unexercised rights decreased from 328,460 to 272,460.

Impact and Future Developments

Because the massive exercising exceeds a certain proportion of listed shares, treatment for exercises exceeding regulatory limits may apply, making appropriate disclosure and monitoring of future trends important. Cases are suggested where restriction clauses under previously concluded purchase agreements may be excluded, so attention should be paid to dilution effects and the linkage with capital policy. It is necessary to confirm whether additional disclosures will be made going forward and to verify the status of treasury share holdings and the financial impact.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

SymBio Pharmaceuticals Limited

Company overview · Stock price · Financial data · All IR

View company page →